TB-500 Safety Profile
TB-500 is not FDA-approved and has not been tested in human clinical trials. It is a synthetic fragment of thymosin beta-4 with no established human safety profile.
Last updated: February 12, 2026
For Educational Purposes Only
This safety information is compiled from clinical trial data and regulatory documents for educational purposes. It is not a substitute for professional medical advice. Always consult your healthcare provider about medication safety, especially regarding your individual circumstances, medical history, and other medications.
Safety Overview
TB-500 (Thymosin Beta-4 Fragment) is not FDA-approved for any use. It is a synthetic peptide derived from a portion of the naturally occurring protein thymosin beta-4. Despite claims in wellness and athletic communities, TB-500 has never been evaluated in human clinical trials.
Level of Evidence: Animal studies and in vitro research only. Zero published human clinical trial data.
What We Don’t Know
TB-500 has not undergone any form of human safety testing, leaving fundamental questions unanswered:
| Unknown Factor | Why It Matters |
|---|---|
| Human safety profile | No systematic evaluation of side effects in humans exists |
| Pharmacokinetics | How the body processes TB-500 is not established |
| Therapeutic window | No evidence-based dose range; all dosing is speculative |
| Long-term effects | Consequences of repeated or chronic use are completely unknown |
| Target population safety | Effects in specific groups (elderly, those with health conditions) unstudied |
| Interaction profile | Potential drug or supplement interactions have not been investigated |
Theoretical Safety Concerns
Wound Healing and Tumor Growth
TB-500 is promoted for its alleged wound healing and tissue repair properties, attributed to its role in:
- Actin regulation: TB-500 affects cell structure and migration
- Angiogenesis: May promote blood vessel formation
- Cell proliferation: May stimulate cell growth and differentiation
These mechanisms raise concerns:
- Cancer risk: Processes that promote tissue repair could theoretically support tumor growth or metastasis
- No oncology data: TB-500 has never been evaluated for cancer safety
- Unregulated proliferation: Effects on abnormal cell growth (pre-cancerous lesions, benign tumors) are unknown
Immune System Effects
As a derivative of thymosin beta-4, which plays a role in immune function, TB-500 could potentially:
- Alter immune responses in unpredictable ways
- Affect inflammatory processes (beneficial or harmful, depending on context)
- Interact with autoimmune conditions
No human data exists to support or refute these theoretical concerns.
Product Quality and Contamination Risks
TB-500 is sold through unregulated research chemical vendors, creating serious quality control issues:
- Peptide purity: Products may contain impurities, degraded peptides, or incorrect sequences
- Bacterial endotoxins: Injectable products could be contaminated with harmful substances
- Dose accuracy: Labeled doses may not reflect actual content
- Sterility concerns: Products marketed for injection may not meet sterility standards
- Complete mislabeling: Some products may not contain TB-500 at all
Regulatory and Legal Status
- FDA Status: Not approved; sale for human use is illegal
- WADA Status: Prohibited substance in all competitive sports
- DEA Status: Not a controlled substance, but illegal to market for human consumption
- International: Not approved in any country for human use
Unknown Long-Term Risks
Because TB-500 has never been studied in humans over time, we cannot assess:
- Effects on cardiovascular health
- Impact on metabolic function
- Neurological effects
- Reproductive or developmental toxicity
- Cumulative toxicity with repeated dosing
TB-500 is an unapproved, untested substance. Any use in humans is an unmonitored experiment with unknown and potentially serious risks. This information is for educational purposes only and does not constitute medical advice.
Safety Alerts
Get notified about new safety data, FDA decisions, and adverse event reports.
No spam. Unsubscribe anytime.
Important: Safety information evolves as post-marketing data accumulates. This page reflects data available as of the last update date. Check official FDA and EMA resources for the most current safety information. This content is not intended to diagnose, treat, cure, or prevent any disease.